Free Trial
Your $100 Credit Expires Tomorrow! Get MarketBeat All Access
  • 0Days
  • 0Hours
  • 0Minutes
  • 0Seconds
Don't Miss Out
Claim MarketBeat All Access Sale Promotion

Cantor Fitzgerald's Rating of Summit Therapeutics on 5/22/2026

On May 22, 2026, Cantor Fitzgerald updated its outlook on Summit Therapeutics (NASDAQ:SMMT) with the action "Reiterated Rating", keeping a "Overweight" rating. MarketBeat All Access subscribers can view the full ratings details, 12-month ROI, historical price target changes, and related news coverage on this page.

unlock icon  Upgrade to MarketBeat All Access

This premium research tool is available to MarketBeat All Access subscribers only. Log in to your account or sign up below.

Already have an account? Log in here.